Perspective Therapeutics (CATX) Update / Briefing January 24, 2025 08:00 AM ET Company Participants Annie Cheng - Vice President of Investor RelationsThijs Spoor - CEO & Member of the Board of DirectorsMarkus Puhlmann - Chief Medical OfficerRichard Wahl - Professor of RadiologyAnish Nikhanj - Senior Associate - Biotechnology Equity ResearchYuan Zhi - Managing DirectorDavid Lai - Executive Director of Equity Capital Markets - AmericasChristopher Liu - Managing DirectorAlec Stranahan - Vice President - Equity ...

Core Insights - Perspective Therapeutics, Inc. announced updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET, presented at the 2025 ASCO-GI symposium, indicating promising anti-tumor activity and a favorable safety profile [1][11] Clinical Trial Overview - The Phase 1/2a clinical trial is a multi-center open-label dose escalation and expansion study targeting patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs) who have not received prior radiopharmaceutical therapy [2] - As of January 10, 2025, all nine patients in the trial had completed treatments, with at least one post-treatment scan available for each [4] Treatment Efficacy - One patient experienced a confirmed objective response lasting 17 weeks, while two additional patients showed initial unconfirmed responses after treatment [5][6][7] - Three out of seven patients in Cohort 2 had investigator-assessed objective responses, with two responses occurring after the treatment period [7][8] Safety Profile - The treatment demonstrated a favorable safety profile, with no dose-limiting toxicities or serious adverse events reported since the study's initiation [8] - Adverse events observed were primarily grade 1 and 2, with no significant decline in renal function noted [8] Future Directions - The company plans to continue dose-finding studies for [212Pb]VMT-α-NET and is engaging with the FDA regarding dose escalation and further patient enrollment [11][13] - Perspective aims to leverage insights from this clinical program to enhance its pipeline and develop new targeted radiopharmaceutical therapies [11][15]

Core Viewpoint - Perspective Therapeutics, Inc. announced the acceptance of an abstract on updated interim results from its Phase 1/2a trial of [Pb]VMT-α-NET for neuroendocrine tumors, to be presented at the ASCO Gastrointestinal Cancers Symposium in January 2025 [1][2] Company Overview - Perspective Therapeutics is a radiopharmaceutical development company focused on advanced treatment applications for various cancers [5] - The company utilizes proprietary technology with the alpha-emitting isotope Pb to target cancer cells specifically, aiming to improve treatment efficacy and minimize toxicity through a "theranostic" approach [5][6] Clinical Trials and Presentations - The interim safety and efficacy data of [Pb]VMT-α-NET will be presented during the "Poster Session B" at the ASCO-GI symposium on January 24, 2025 [2] - A conference call will be held on January 24, 2025, to discuss the data presented, featuring the lead investigator and members of the management team [3] Research and Development - The company is conducting Phase 1/2a imaging and therapy trials for its melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs at leading academic institutions [6] - Perspective has developed a proprietary Pb generator to secure key isotopes for clinical trials and commercial operations [6]

Core Insights - Perspective Therapeutics is focusing on advancing its clinical pipeline and expanding its manufacturing capabilities over the next 12-18 months [2][6][18] Clinical Pipeline Advancements - The company is conducting a multi-center open-label dose escalation study of [212Pb]VMT-α-NET for patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors [3] - Initial results from the study indicated no dose-limiting toxicities and two grade 3 adverse events, with eight of nine patients showing durable disease control [5][8][16] - The VMT01 program is also in a dose escalation study for previously treated melanoma patients, with initial results presented at a recent conference [9][10] Financial Position - As of December 31, 2024, the company reported preliminary unaudited cash, cash equivalents, and short-term investments of approximately $227.8 million, expected to fund operations into late 2026 [6][14][15] Manufacturing and Infrastructure - The company is working on expanding its manufacturing capabilities by improving existing facilities and evaluating additional capacity expansion opportunities [6][22] - Plans include building out recently acquired sites to enhance the availability of its medicines [6][22] Upcoming Events - The company will present updates at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 [17]

Core Insights - Perspective Therapeutics, Inc. is a radiopharmaceutical company focused on advanced cancer treatment applications [3] - The company will present at the 43rd Annual J.P. Morgan Healthcare Conference and the Biotech Showcase in January 2025 [1][2] Company Overview - Perspective Therapeutics specializes in developing radiopharmaceuticals using the alpha-emitting isotope Pb to target cancer cells [3] - The company is also working on complementary imaging diagnostics to personalize treatment and improve patient outcomes through a "theranostic" approach [3] Clinical Development - The company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs are currently in Phase 1/2a trials at leading academic institutions [4] - Perspective has developed a proprietary Pb generator to secure key isotopes for clinical trials and commercial operations [4]

SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the appointment of Juan Graham as the Company’s Chief Financial Officer (CFO), effective as of January 6, 2025. In connection with the transition, Jonathan Hunt will no longer serve as CFO but will continue serving as the Company’s Chief Accounting Off ...

My name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degree in Business Management from Universidad Andina Simon Bolivar, Quito, Ecuador, and the Ph.D. degree in computer applications from the University of Alicante, Spain.Disclosure: I collaborate professionally with Edgar Torres H, who is also an author on Seeking ...

When I first covered Perspective Therapeutics (NYSE: CATX ) earlier this year , I expressed interest and optimism for their approach of a novel peptide receptor radionuclide therapy (PRRT), which could be of use inI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of ...

SEATTLE, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences. 36th Annual Piper Healthcare ConferenceDate: December 3, 2024Location: New York, NYFo ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 001-33407 | --- | --- | |----------------------------------------------------------------------- ...